Gianluca Quintini

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 175 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Virology +16

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 132 citations · Full text

Veterinary Medicine, Immunology, Molecular Pharmaceutics +17

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter G. Kremsner, Philipp Mann, Jacobus J. Bosch et al. · medRxiv · 2020 · 103 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK)

Avdhoot Velankar, Gianluca Quintini, Arati Prabhu et al. · Bioorganic & Medicinal Chemistry · 2010 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen

Matthias Schröder, Cornelia Richter, Martina Herrero San Juan et al. · Molecular Immunology · 2011 · 35 citations

Life Sciences, Cell Biology, Immunology +16